SGLT2 inhibitors × adverse events & safety

TrialEuropean heart journal2021

Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.

Brendon L Neuen et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 4,401 people · 2021

Randomised comparison

Lowered adverse events & safety

−22%−36% to −5%

Bigger than 5 in 10 for adverse events & safety

As reported

HR 0.78, 95% CI 0.64–0.95

One number in the abstract

the abstract, start to end

1000 patient-years; hazard ratio (HR) 0.78, 95% confidence interval (CI)

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
HR 0.780.64–0.95
SGLT2 inhibitorsAdverse events & safety

SGLT2 inhibitors × adverse events & safetyharms?mixed

unlikelylikely
0.000.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

57 papers cite it

2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 34423370